Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Sharkey

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
International Journal of Cancer|August 4, 1998
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacyT M Behr, S Memtsoudis, R M Sharkey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigenM Juweid, R M Sharkey, T Behr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignanciesT M Behr, B Wörmann, M Gramatzki, et al.
Cancer Research|February 1, 1990
Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTcD M Goldenberg, H Goldenberg, R M Sharkey, et al.
Cancer|December 24, 1997
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetryT M Behr, R M Sharkey, G Sgouros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emittersT M Behr, G Sgouros, M G Stabin, et al.
Cancer Research|September 1, 1995
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivativesT M Behr, R M Sharkey, M E Juweid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1993
Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragmentsD M Goldenberg, T J Wlodkowski, R M Sharkey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1997
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgGT M Behr, R M Sharkey, M E Juweid, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1997
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22R M Sharkey, T M Behr, M J Mattes, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
International Journal of Cancer|August 4, 1998
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacyT M Behr, S Memtsoudis, R M Sharkey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigenM Juweid, R M Sharkey, T Behr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignanciesT M Behr, B Wörmann, M Gramatzki, et al.
Cancer Research|February 1, 1990
Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTcD M Goldenberg, H Goldenberg, R M Sharkey, et al.
Cancer|December 24, 1997
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetryT M Behr, R M Sharkey, G Sgouros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emittersT M Behr, G Sgouros, M G Stabin, et al.
Cancer Research|September 1, 1995
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivativesT M Behr, R M Sharkey, M E Juweid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1993
Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragmentsD M Goldenberg, T J Wlodkowski, R M Sharkey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1997
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgGT M Behr, R M Sharkey, M E Juweid, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1997
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22R M Sharkey, T M Behr, M J Mattes, et al.
Pageof 15